IndustryCompany release
BrainStorm posts $1.7M Q3 net loss as NurOwn Phase 3b ALS trial awaits start
🇺🇸 Brainstorm Cell Therapeutics Inc. (BCLI) · Mon 16 Nov 2026
The cell therapy developer reports minimal cash of about $0.35M while still preparing its ENDURANCE study in earlier-stage ALS under an FDA-agreed Special Protocol Assessment.
BrainStorm Cell Therapeutics reported results for the quarter ended 30 September 2026 on 16 November, disclosing a net loss of about $1.7M. Cash and restricted cash totalled roughly $0.35M at the end of the period.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Brainstorm Cell Therapeutics Inc. ↗
Article written by VigiEye from the official source (Brainstorm Cell Therapeutics Inc.). Claims are the company's own. AI-assisted; check the source before acting.
More Industry
All →
Gedeon Richter to acquire Mayne Pharma in AUD 604 million cash deal
Gedeon Richter · Mon 16 Nov 2026
Metagenomi puts hemophilia A editing candidate MGX-001 first in November 2026 deck
🇺🇸 Metagenomi Therapeutics, Inc. (MGX) · Mon 16 Nov 2026
Lifeloc Q3 revenue rises 12% as SpinDetect drug analyzer launch slips to Q4 2027
🇺🇸 Lifeloc Technologies, Inc (LCTC) · Mon 16 Nov 2026
Aytu BioPharma to be acquired by Rosemont for about $56M as EXXUA sales grow
🇺🇸 Aytu Biopharma, Inc (AYTU) · Mon 16 Nov 2026
Merck KGaA to acquire Rapid Micro Biosystems in $0.75-per-share cash tender offer
🇺🇸 Rapid Micro Biosystems, Inc. (RPID) · Mon 16 Nov 2026
Glass House Brands more than doubles Q3 revenue to $56.8M as net loss narrows
Glass House Brands Inc. (GLAS) · Mon 16 Nov 2026